JC
ELVN icon

JBF Capital’s Enliven Therapeutics ELVN Stock Holding History

JBF Capital’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-27,006
Closed -$369K – 78
2023
Q3 		$369K Sell
27,006
-23,044
-46% -$388K 0.08% 46
2023
Q2 		$1.02M Hold
50,050
– – 0.21% 26
2023
Q1 		$1.1M Hold
50,050
– – 0.25% 28
2022
Q4 		$819K Sell
50,050
-2,450
-5% -$39.2K 0.2% 26
2022
Q3 		$479K Buy
+52,500
New +$310K 0.12% 32

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JBF Capital's ELVN Position: Q4 2023 in Review

JBF Capital sold out of Enliven Therapeutics (ELVN) in Q4 2023, closing a stake of 27,006 shares — an estimated $369K sold.

JBF Capital first reported a position in ELVN in Q3 2022 and held it in 5 quarters. The position peaked at $1.1M in Q1 2023. 62 funds tracked by Wall St. Rank hold ELVN as of Q4 2023.

  • JBF Capital reported no remaining Enliven Therapeutics position as of Q4 2023 after selling out during the quarter.
  • JBF Capital sold 27,006 Enliven Therapeutics shares in Q4 2023, an estimated $369K.
  • JBF Capital first reported a position in Enliven Therapeutics in Q3 2022 and held it in 5 quarters.
  • JBF Capital's Enliven Therapeutics position peaked at $1.1M in Q1 2023.
  • 62 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q4 2023.

Based on JBF Capital's 13F filing for Q4 2023, filed 13 Feb 2024.